Abstract
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? Candida auris (C. auris) is an emerging multidrug-resistant fungal pathogen classified as a global public health threat with notable mortality and nosocomial transmission capacity. In China, the first C. auris case was reported from Beijing in 2018. However, large cases of nosocomial transmission have rarely been identified in this municipality. WHAT IS ADDED BY THIS REPORT? During March-September 2023, C. auris was isolated from 17 patients admitted to CY Hospital in Beijing. All strains were resistant to fluconazole and amphotericin B. In addition, three isolates were resistant to echinocandins. Whole-genome sequencing (WGS) analysis revealed that all strains found in this hospital belonged to C. auris Clade I. These strains were genetically closely related to the C. auris strains reported in two other hospitals in Beijing since 2021, forming a new sublineage different from the Clade I strains causing previous outbreaks in the Eastern Provincial-level administrative divisions and Hong Kong Special Administrative Region. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? The dissemination of C. auris has become an increasing threat to healthcare facilities in China. The WGS analysis indicates the spread of a unique sublineage of C. auris Clade I isolates in Beijing. Further, enhanced surveillance and hospital infection control of C. auris are warranted to resolve the public health challenge.